In Annex VI to Regulation (EC) No 1272/2008, Table 3 of Part 3 is amended as follows:
the following entries are inserted following the order of the index numbers corresponding to each entry:
Index No | Chemical Name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M- factors and ATE | Notes
Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s)
‘015-204-00-5 | benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate | 479-100-5 | 577705-90-9 | Repr. 1B | H360F |
GHS08
Dgr
H360F’ | | |
‘015-205-00-0 | benzyltriphenylphosphonium, salt with 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]bis[phenol] (1:1) | 278-305-5 | 75768-65-9 | Repr. 1B | H360F |
GHS08
Dgr
H360F’ | | |
‘015-206-00-6 | reaction mass of 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol and benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate (1:1) | — | — | Repr. 1B | H360F |
GHS08
Dgr
H360F’ | | |
‘015-207-00-1 | reaction mass of 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol and benzyltriphenylphosphonium, salt with 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol (1:1) | — | — | Repr. 1B | H360F |
GHS08
Dgr
H360F’ | | |
‘015-208-00-7 | dimethyl propylphosphonate | 242-555-3 | 18755-43-6 |
Muta. 1B
Repr. 1B
H340
H360Df
GHS08
Dgr
H340
H360Df’
‘050-034-00-5 | dibutyltin maleate | 201-077-5 | 78-04-6 |
Muta. 2
Repr. 1B
Acute Tox. 2
Acute Tox. 4
STOT RE 1
Skin Corr. 1
Eye Dam. 1
H341
H360FD
H330
H302
H372 (immune system)
H314
H318
GHS08
GHS06
GHS05
Dgr
H341
H360FD
H330
H302
H372 (immune system)
H314
inhalation:
ATE = 0,317 mg/L (dusts or mists)
oral:
ATE = 510 mg/kg bw’
‘050-035-00-0 | dibutyltin oxide | 212-449-1 | 818-08-6 |
Muta. 2
Repr. 1B
Acute Tox. 3
STOT RE 1
Skin Irrit. 2
Eye Dam. 1
H341
H360FD
H301
H372 (immune system)
H315
H318
GHS08
GHS06
GHS05
Dgr
H341
H360FD
H301
H372 (immune system)
H315
H318
oral:
ATE = 170 mg/kg bw’
‘603-244-00-1 | reaction mass of 1-(2,3-epoxypropoxy)–2,2-bis ((2,3-epoxypropoxy)methyl) butane and 1-(2,3-epoxypropoxy)-2-((2,3-epoxypropoxy)methyl)-2-hydroxymethyl butane | — | — |
Muta. 2
Repr. 1B
H341
H360F
GHS08
Dgr
H341
H360F’
‘603-245-00-7 | 2,2'-[[3-methyl-4-[(4-nitrophenyl)azo]phenyl]imino]bisethanol | 221-665-5 | 3179-89-3 | Skin Sens. 1 | H317 |
GHS07
Wng
H317’ | | |
‘603-246-00-2 | 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-1-ol | 211-477-1 | 647-42-7 |
STOT RE 2
Aquatic Chronic 1
H373 (teeth, bones)
H410
GHS08
GHS09
Wng
H373 (teeth, bones)
H410
M = 1’ |
‘604-099-00-7 | 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol; bisphenol AF | 216-036-7 | 1478-61-1 | Repr. 1B | H360F |
GHS08
Dgr
H360F’ | | |
‘604-100-00-0 | nonylphenol, branched and linear, ethoxylated (with average molecular weight ≤ 1540 g/mol) [includes ortho-, meta-, para- isomers or any combination thereof] |
500-315-8
500-024-6
500-045-0
500-209-1
248-762-5
243-816-4
248-291-5
—
230-770-5 248-743-1 247-555-7 248-293-6
—
and others
127087-87-0
9016-45-9
26027-38-3
68412-54-4
27986-36-3
20427-84-3
27176-93-8
1119449-38-5 7311-27-5 27942-27-4 26264-02-8 27177-05-5 14409-72-4 and others
Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410 | |
M = 1
M = 10’
‘606-155-00-6 |
cinnamaldehyde; 3-phenylprop-2-enal;
cinnamic aldehyde; cinnamal; [1]
(2E)-3-phenylprop-2-enal [2]
203-213-9 [1] - [2] | 104-55-2 [1] 14371-10-9 [2] | Skin Sens. 1A | H317 |
GHS07
Wng
H317 | | Skin Sens. 1; H317: C ≥ 0,01 %’ |
‘607-766-00-0 | tetramethylene dimethacrylate | 218-218-1 | 2082-81-7 | Skin Sens. 1B | H317 |
GHS07
Wng
H317’ | | |
‘607-767-00-6 | 7,7,9(or 7,9,9)-trimethyl–4,13-dioxo–3,14-dioxa–5,12-diazahexadecane–1,16-diyl bismethacrylate | 276-957-5 | 72869-86-4 | Skin Sens. 1B | H317 |
GHS07
Wng
H317’ | | |
‘607-768-00-1 | 2,2'-ethylenedioxydiethyl dimethacrylate | 203-652-6 | 109-16-0 | Skin Sens. 1B | H317 |
GHS07
Wng
H317’ | | |
‘607-769-00-7 | bifenox (ISO); methyl 5-(2,4-dichlorophenoxy)-2-nitrobenzoate | 255-894-7 | 42576-02-3 |
Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1
H302
H400
H410
GHS07
GHS09
Wng
H302
H410
oral:
ATE = 1500 mg/kg bw
M = 1000
M = 1000’
‘612-295-00-9 | benfluralin (ISO); N-butyl-N-ethyl-α,α,α-trifluoro-2,6-dinitro-p-toluidine | 217-465-2 | 1861-40-1 |
Carc. 2
Repr. 2
Skin Irrit. 2
Eye Irrit. 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H351
H361d
H315
H319
H317
H400
H410
GHS08
GHS07
GHS09
Wng
H351
H361d
H315
H319
H317
H410
M = 10
M = 10’
‘612-296-00-4 | N,N-dimethyl-p-toluidine | 202-805-4 | 99-97-8 |
Carc. 1B
Acute Tox. 4
Acute Tox. 3
STOT RE 2
Aquatic Chronic 3
H350
H332
H301
H373 (blood system, respiratory tract)
H412
GHS08
GHS06
Dgr
H350
H332
H301
H373 (blood system, respiratory tract)
H412
inhalation:
ATE = 1,4 mg/L (dusts or mists)
oral:
ATE = 140 mg/kg bw’
‘612-297-00-X | 1-phenylethan-1-one (1-phenylethylidene)hydrazone | 211-979-0 | 729-43-1 | Skin Sens. 1 | H317 |
GHS07
Wng
H317’ | | |
‘612-298-00-5 | 1,4-Benzenediamine, N,N’-mixed Ph and tolyl derivs.; | 273-227-8 | 68953-84-4 |
Repr. 1B
Skin Sens. 1
H360FD
H317
GHS08
GHS07
Dgr
H360FD
H317’
‘613-346-00-8 | 4-nitrosomorpholine | — | 59-89-2 |
Carc. 1B
Muta. 2
STOT RE 1
H350
H341
H372 (liver)
GHS08
Dgr
H350
H341
H372 (liver)
Carc. 1B; H350: C ≥ 0,001 %’ |
‘613-347-00-3 | difenoconazole (ISO); 1-({2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl–1,3-dioxolan-2-yl}methyl)-1H-1,2,4-triazole; 3-chloro-4-[(2RS,4RS;2RS,4SR)-4-methyl-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-2-yl]phenyl 4-chlorophenyl ether | — | 119446-68-3 |
Carc. 2
Acute Tox. 4
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1
H351
H302
H319
H400
H410
GHS08
GHS07
GHS09
Wng
H351
H302
H319
H410
oral:
ATE = 1450 mg/kg bw
M = 10
M = 10’
‘613-348-00-9 | 9-[2-(ethoxycarbonyl)phenyl]–3,6-bis(ethylamino)–2,7-dimethylxanthylium chloride; Basic Red 1 | 213-584-9 | 989-38-8 |
Acute Tox. 3
Eye Dam. 1
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H301
H318
H317
H400
H410
GHS06
GHS05
GHS09
Dgr
H301
H318
H317
H410
oral:
ATE = 280 mg/kg bw
M = 10
M = 1’
‘613-349-00-4 | 4-methylimidazole | 212-497-3 | 822-36-6 |
Carc. 1B
Repr. 1B
H350
H360Fd
GHS08
Dgr
H350
H360Fd’
‘615-051-00-X | 3,3'-dimethylbiphenyl–4,4'-diyl diisocyanate | 202-112-7 | 91-97-4 |
Carc. 2
Resp. Sens. 1
Skin Sens. 1A
H351
H334
H317
GHS08
Dgr
H351
H334
H317
Skin Sens. 1A; H317: C ≥ 0,001 %’ |
‘616-241-00-5 | foramsulfuron (ISO); 2-{[(4,6-dimethoxypyrimidin-2-yl)carbamoyl]sulfamoyl}-4-formamido-N,N-dimethylbenzamide; 1-(4,6-dimethoxypyrimidin-2-yl)-3-(2-dimethylcarbamoyl-5-formamidophenylsulfonyl)urea | — | 173159-57-4 |
Carc. 2
Aquatic Acute 1
Aquatic Chronic 1
H351
H400
H410
GHS08
GHS09
Wng
H351
H410
M = 1000
M = 100’
‘616-242-00-0 | picolinafen (ISO); N-(4-fluorophenyl)-6-[3-(trifluoromethyl)phenoxy]pyridine-2-carboxamide; 4′-fluoro-6-[(α,α,α-trifluoro-m-tolyl)oxy]picolinanilide | — | 137641-05-5 |
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1
H373 (blood system, thyroid)
H400
H410
GHS08
GHS09
Wng
H373 (blood system, thyroid)
H410
M = 1000
M = 1000’
the entries corresponding to index numbers 006-015-00-9; 015-203-00-X; 016-001-00-4; 016-011-00-9; 017-004-00-3; 017-005-00-9; 082-013-00-1; 082-014-00-7; 603-057-00-5; 604-010-00-1; 604-074-00-0; 606-034-00-8; 607-032-00-X; 607-034-00-0; 607-223-00-8; 607-246-00-3; 612-004-00-5; 612-049-00-0; 612-056-00-9; 613-088-00-6; 613-127-00-7; 613-307-00-5; 616-035-00-5; 616-104-00-X are replaced by the following entries respectively:
Index No | Chemical Name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors and ATE | Notes
Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s)
‘006-015-00-9 | diuron (ISO); 3-(3,4-dichlorophenyl)–1,1-dimethylurea | 206-354-4 | 330-54-1 |
Carc. 1B
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1
H350
H373 (blood system)
H400
H410
GHS08
GHS09
Dgr
H350
H373 (blood system)
H410
M = 100
M = 100’
‘015-203-00-X | diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide | 278-355-8 | 75980-60-8 |
Repr. 1B
Skin Sens. 1B
H360Fd
H317
GHS08
GHS07
Dgr
H360Fd
H317’
‘016-001-00-4 | hydrogen sulphide, hydrogen sulfide | 231-977-3 | 7783-06-4 |
Flam. Gas 1A
Press. Gas
Acute Tox. 2
Aquatic Acute 1
H220
H330
H400
GHS02
GHS06
GHS09
Dgr
H220
H330
H400
inhalation: ATE = 440 ppmV (gases) | U’
‘016-011-00-9 | sulphur dioxide; sulfur dioxide | 231-195-2 | 7446-09-5 |
Press. Gas
Acute Tox. 3
STOT SE 1
Skin. Corr. 1B
H331
H370 (respiratory system) (inhalation)
H314
GHS04
GHS06
GHS08
GHS05
Dgr
H331
H370 (respiratory system) (inhalation)
H314
inhalation: ATE = 1000 ppmV (gases) | U, 5’
‘017-004-00-3 | potassium chlorate | 223-289-7 | 3811-04-9 |
Ox. Sol. 1
Acute Tox. 3
H271
H301
GHS03
GHS06
Dgr
H271
H301
oral: ATE = 100 mg/kg bw’ |
‘017-005-00-9 | sodium chlorate | 231-887-4 | 7775-09-9 |
Ox. Sol. 1
Acute Tox. 3
H271
H301
GHS03
GHS06
Dgr
H271
H301
oral: ATE = 100 mg/kg bw’ |
‘082-013-00-1 |
lead powder;
[particle diameter < 1 mm]
231-100-4 | 7439-92-1 |
Repr. 1A
Lact.
Aquatic Acute 1
Aquatic Chronic 1
H360FD
H362
H400
H410
GHS08
GHS09
Dgr
H360FD
H362
H410
Repr. 1A;
H360D: C ≥ 0,03 %
M = 10
M = 100’
‘082-014-00-7 |
lead massive:
[particle diameter ≥ 1 mm]
231-100-4 | 7439-92-1 |
Repr. 1A
Lact.
Aquatic Chronic 1
H360FD
H362
H410
GHS08
GHS09
Dgr
H360FD
H362
H410
M = 10’ |
‘603-057-00-5 | benzyl alcohol | 202-859-9 | 100-51-6 |
Acute Tox. 4
Eye Irrit. 2
Skin Sens. 1B
H302
H319
H317
GHS07
Wng
H302
H319
H317
oral: ATE = 1200 mg/kg bw’ |
‘604-010-00-1 | resorcinol; 1,3-benzenediol | 203-585-2 | 108-46-3 |
Acute Tox. 4
STOT SE 1
Skin Irrit. 2
Eye Irrit. 2
Skin Sens. 1B
Aquatic Acute 1
H302
H370 (nervous system)
H315
H319
H317
H400
GHS07
GHS08
GHS09
Dgr
H302
H370 (nervous system)
H315
H319
H317
H400
oral: ATE = 500 mg/kg bw
M = 1’
‘604-074-00-0 | 2,2',6,6'-tetrabromo–4,4'-isopropylidenediphenol; tetrabromobisphenol-A | 201-236-9 | 79-94-7 |
Carc. 1B
Aquatic Acute 1
Aquatic Chronic 1
H350
H400
H410
GHS08
GHS09
Dgr
H350
H410’
‘606-034-00-8 | metribuzin (ISO); 4-amino-6-tert-butyl-3-methylthio-1,2,4-triazin-5(4H)-one; 4-amino-4,5-dihydro-6-(1,1-dimethylethyl)-3-methylthio-1,2,4-triazin-5-one | 244-209-7 | 21087-64-9 |
Acute Tox. 4
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1
H302
H373 (blood system)
H400
H410
GHS07
GHS08
GHS09
Wng
H302
H373 (blood system)
H410
oral: ATE = 320 mg/kg bw
M = 10
M = 10’
‘607-032-00-X | ethyl acrylate | 205-438-8 | 140-88-5 |
Flam. Liq. 2
Acute Tox. 3
Acute Tox. 4
Acute Tox. 4
STOT SE 3
Skin Irrit. 2
Eye Irrit. 2
Skin Sens. 1
H225
H331
H312
H302
H335
H315
H319
H317
GHS02
GHS06
Dgr
H225
H331
H312
H302
H335
H315
H319
H317
inhalation: ATE = 9 mg/L (vapours)
dermal: ATE = 1800 mg/kg bw
oral: ATE = 1120 mg/kg bw
STOT SE 3; H335: C ≥ 5 %
Skin Irrit. 2; H315: C ≥ 5 %
Eye Irrit. 2; H319: C ≥ 5 %
D’
‘607-034-00-0 |
methyl acrylate;
methyl propenoate
202-500-6 | 96-33-3 |
Flam. Liq. 2
Acute Tox. 3
Acute Tox. 4
Acute Tox. 4
STOT SE 3
Skin Irrit. 2
Eye Irrit. 2
Skin Sens. 1
H225
H331
H312
H302
H335
H315
H319
H317
GHS02
GHS06
Dgr
H225
H331
H312
H302
H335
H315
H319
H317
inhalation: ATE = 3 mg/L (vapours)
dermal: ATE = 1100 mg/kg bw
oral: ATE = 500 mg/kg bw
D’
‘607-223-00-8 | transfluthrin (ISO); 2,3,5,6-tetrafluorobenzyl (1R,3S)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate | 405-060-5 | 118712-89-3 |
Carc. 2
Acute Tox. 4
STOT SE 1
Aquatic Acute 1
Aquatic Chronic 1
H351
H302
H370 (nervous system)
H400
H410
GHS08
GHS07
GHS09
Wng
H351
H302
H370 (nervous system)
H410
EUH066 |
oral: ATE = 580 mg/kg bw
M = 1000
M = 1000’
‘607-246-00-3 |
allyl methacrylate;
2-methyl-2-propenoic acid 2-propenyl ester
202-473-0 | 96-05-9 |
Flam. Liq. 3
Acute Tox. 2
Acute Tox. 3
Acute Tox. 4
Aquatic Acute 1
H226
H330
H311
H302
H400
GHS02
GHS06
GHS09
Dgr
H226
H330
H311
H302
H400
inhalation: ATE = 1,5 mg/L (vapours)
dermal: ATE = 300 mg/kg bw
oral: ATE = 400 mg/kg bw’
‘612-004-00-5 | triethylamine | 204-469-4 | 121-44-8 |
Flam. Liq. 2
Acute Tox. 3
Acute Tox. 3
Acute Tox. 3
Skin Corr. 1A
Eye Dam. 1
H225
H331
H311
H301
H314
H318
GHS02
GHS06
GHS05
Dgr
H225
H331
H311
H301
H314
inhalation: ATE = 7,2 mg/L (vapours)
dermal: ATE = 300 mg/kg bw
oral: ATE = 100 mg/kg bw STOT SE 3; H335: C ≥ 1 %’
‘612-049-00-0 | di-n-butylamine | 203-921-8 | 111-92-2 |
Flam. Liq. 3
Acute Tox. 2
Acute Tox. 3
Acute Tox. 3
Skin Corr. 1B
Eye Dam. 1
H226
H330
H311
H301
H314
H318
GHS02
GHS06
GHS05
Dgr
H226
H330
H311
H301
H314
EUH 071 |
inhalation: ATE = 1,2 mg/L (vapours) dermal: ATE = 300 mg/kg bw
oral: ATE = 220 mg/kg bw’
‘612-056-00-9 |
N,N-dimethyl-m-toluidine; [1]
N,N-dimethyl-o-toluidine [2]
204-495-6 [1] 210-199-8 [2] | 121-72-2 [1] 609-72-3 [2] | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 3 |
H331
H311
H301
H373 **
H412
GHS06 GHS08
Dgr
H331
H311
H301
H373 **
H412
* | C’
‘613-088-00-6 | 1,2-benzisothiazol-3(2H)-one; 1,2-benzisothiazolin-3-one | 220-120-9 | 2634-33-5 |
Acute Tox. 2
Acute Tox. 4
Skin Irrit. 2
Eye Dam. 1
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 1
H330
H302
H315
H318
H317
H400
H410
GHS06
GHS05
GHS09
Dgr
H330
H302
H315
H318
H317
H410
inhalation:
ATE = 0,21 mg/L (dusts or mists)
oral: ATE = 450 mg/kg bw
Skin Sens. 1A; H317: C ≥ 0,036 %
M = 1
M = 1’
‘613-127-00-7 | mepiquat chloride (ISO); 1,1-dimethylpiperidinium chloride | 246-147-6 | 24307-26-4 |
Acute Tox. 4
Acute Tox. 3
Aquatic Chronic 3
H332
H301
H412
GHS06
Dgr
H332
H301
H412
inhalation: ATE = 2,8 mg/L (dusts or mists)
oral:
ATE = 270 mg/kg bw’
‘613-307-00-5 | clothianidin (ISO); (E)-1-(2-chloro–1,3-thiazol-5-ylmethyl)-3-methyl-2-nitroguanidine | 433-460-1 | 210880-92-5 |
Repr. 2
Acute Tox. 4
STOT SE 1
Aquatic Acute 1
Aquatic Chronic 1
H361f
H302
H370 (nervous system)
H400
H410
GHS08
GHS07
GHS09
Dgr
H361f
H302
H370 (nervous system)
H410
oral: ATE = 390 mg/kg bw
M = 10
M = 100’
‘616-035-00-5 |
cymoxanil (ISO); 2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide; [1]
(2E)-2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide; [2]
261-043-0 [1]
[2]
57966-95-7 [1]
166900-80-7 [2]
Repr. 2
Acute Tox. 4
STOT RE 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H361fd
H302
H373 (blood system, thymus, eyes)
H317
H400
H410
GHS08
GHS07
GHS09
Wng
H361fd
H302
H373 (blood system, thymus, eyes)
H317
H410
oral: ATE = 360 mg/kg bw
M = 1
M = 1’
‘616-104-00-X | benalaxyl (ISO); methyl N-(2,6-dimethylphenyl)-N-(phenylacetyl)-DL-alaninate | 275-728-7 | 71626-11-4 |
Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1
H302
H400
H410
GHS07
GHS09
Wng
H302
H410
oral: ATE = 1000 mg/kg bw
M = 1
M = 1’